Lessons Still To Learn: Cytokinetics’ Omecamtiv Is Over In The US, But FDA Debriefs Could Inform European Strategy

 
• By Bridget Silverman

Cytokinetics will not conduct the new trial in heart failure with reduced ejection fraction (HFrEF) required by the FDA’s complete response letter for omecamtiv mecarbil.

heart with green background
• Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers